Literature DB >> 9024334

New therapeutic approaches to Alzheimer's disease.

L S Schneider1.   

Abstract

Therapeutic approaches to treat the cognitive impairment in dementia and to treat slow decline are making their way into clinical practice. Cholinergic agents are currently the most promising treatment, and several cholinesterase inhibitors will soon be available for prescription. As physicians learn more about dosing, side effects, and mechanisms of action, they can prescribe these drugs more efficiently. Evidence suggests that certain patients with dementia may be particularly responsive to such intervention, and other medications may enhance response. Current experimental approaches to slowing the rate of cognitive decline include the use of antioxidants, monoamine oxidase-B inhibitors, cholinesterase inhibitors, and anti-inflammatory agents. Psychosocial interventions appear to help delay institutionalization. Drugs that improve cognition also may affect behavioral symptoms and severe dementia as well as non-Alzheimer dementia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9024334

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  12 in total

1.  Donepezil helps alleviate nightmares associated with posttraumatic stress disorder and other psychiatric conditions: a report of 4 cases.

Authors:  Mohammad Farooque
Journal:  Prim Care Companion CNS Disord       Date:  2012-08-30

Review 2.  Advances and challenges in the prevention and treatment of Alzheimer's disease.

Authors:  R Diaz Brinton; R S Yamazaki
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

3.  Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group.

Authors:  G K Wilcock; S Lilienfeld; E Gaens
Journal:  BMJ       Date:  2000-12-09

4.  Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.

Authors:  K Rockwood; J Mintzer; L Truyen; T Wessel; D Wilkinson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-11       Impact factor: 10.154

5.  Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.

Authors:  Dong-Churl Suh; Stephen Arcona; Simu K Thomas; Christopher Powers; Adrian L Rabinowicz; Hyunchul Shin; Dario Mirski
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

6.  Acetylcholinesterase inhibition by flavonoids from Agrimonia pilosa.

Authors:  Mankil Jung; Moonso Park
Journal:  Molecules       Date:  2007-09-03       Impact factor: 4.411

7.  Correlation between antibutyrylcholinesterasic and antioxidant activities of three aqueous extracts from Tunisian Rhus pentaphyllum.

Authors:  Hedi Ben Mansour; Sonia Yatouji; Sihem Mbarek; Ikram Houas; Afef Delai; Dorra Dridi
Journal:  Ann Clin Microbiol Antimicrob       Date:  2011-08-31       Impact factor: 3.944

8.  Investigations of anticholinestrase and antioxidant potentials of methanolic extract, subsequent fractions, crude saponins and flavonoids isolated from Isodon rugosus.

Authors:  Anwar Zeb; Abdul Sadiq; Farhat Ullah; Sajjad Ahmad; Muhammad Ayaz
Journal:  Biol Res       Date:  2014-12-26       Impact factor: 5.612

9.  In Vitro Anti-AChE, Anti-BuChE, and Antioxidant Activity of 12 Extracts of Eleutherococcus Species.

Authors:  Daniel Załuski; Rafał Kuźniewski
Journal:  Oxid Med Cell Longev       Date:  2016-10-10       Impact factor: 6.543

10.  Assessment of Anticholinesterase Activity of Gelidiella acerosa: Implications for Its Therapeutic Potential against Alzheimer's Disease.

Authors:  Arif Nisha Syad; Karutha Pandian Shunmugiah; Pandima Devi Kasi
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-06       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.